TDP-43: a novel neurodegenerative proteinopathy

Current Opinion in Neurobiology

Volumn 17, Issue 5, 2007, Pages 548-555

  Forman, Mark S ^a   Trojanowski, John Q ^a   Lee, Virginia M Y ^a  

^a Institute on Aging   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; TDP 43 PROTEIN; UNCLASSIFIED DRUG;

AMYLOIDOSIS; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN REGION; CARBOXY TERMINAL SEQUENCE; CLINICAL ASSESSMENT; DEGENERATIVE DISEASE; FRONTAL LOBE; HUMAN; NEUROPATHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; TEMPORAL LOBE; UBIQUITINATION;

AMYOTROPHIC LATERAL SCLEROSIS; DEMENTIA; DNA-BINDING PROTEINS; HUMANS; UBIQUITIN;

EID: 37549012160     PISSN: 09594388     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conb.2007.08.005     Document Type: Review

References (49)

1. Forman M.S., Trojanowski J.Q., and Lee V.M.-Y. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10 (2004) 1055-1063
2. Kumar-Singh S., and Van B.C. Frontotemporal lobar degeneration: current concepts in the light of recent advances. Brain Pathol 17 (2007) 104-114. This is an outstanding review summarizing recent advances in genetics, biochemistry, and pathology in FTLD research.
3. Xiao S., McLean J., and Robertson J. Neuronal intermediate filaments and ALS: a new look at an old question. Biochim Biophys Acta 1762 (2006) 1001-1012
4. Cairns N.J., Bigio E.H., Mackenzie I.R.A., Neumann M., Lee V.M.Y., Hatanpaa K.J., White III C.L., Schneider J.A., Grinberg L.T., Halliday G., et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 1145 (2007) 5-22. This is a consensus paper on revised criteria for the neuropathological diagnosis of FTLD that incorporates recent advances in molecular genetics, biochemistry, and neuropathology including the identification of TDP-43 as the major disease protein in FTLD-U. The proposed classification scheme includes an algorithm for the neuropathological diagnosis of FTLD and is compared with the previous classification system described in 2001 [16].
5. Cruts M., Gijselinck I., van der Z.J., Engelborghs S., Wils H., Pirici D., Rademakers R., Vandenberghe R., Dermaut B., Martin J.J., et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442 (2006) 920-924. This study reports about the identification of PGRN mutations in patients with frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) and FTLD-U pathology. Interestingly, PGRN is located on chromosome 17q21, 1.7 Mb centromeric of MAPT, in which mutations are associated with FTDP-17 with tau pathology. All of the mutations in PGRN were predicted to cause premature termination of the coding sequence by nonsense-mediated decay of mutant mRNAs. In one large Belgian kindred, mutations were identified in the splice donor site of intron 0 causing loss of mutant transcript by nuclear degradation.
6. Baker M., Mackenzie I.R., Pickering-Brown S.M., Gass J., Rademakers R., Lindholm C., Snowden J., Adamson J., Sadovnick A.D., Rollinson S., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442 (2006) 916-919. This study reports about the first identification of PGRN mutations in patients with FTDP-17 and FTLD-U pathology. Interestingly, PGRN is located on chromosome 17q21, 1.7 Mb centromeric of MAPT, and encodes for 68-kDa secreted growth factor. All of the mutations in PGRN were predicted to cause premature termination of the coding sequence by nonsense-mediated decay of mutant mRNAs. The authors propose that the mutations cause disease by haploinsufficiency.
7. Watts G.D., Wymer J., Kovach M.J., Mehta S.G., Mumm S., Darvish D., Pestronk A., Whyte M.P., and Kimonis V.E. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36 (2004) 377-381
8. Forman M.S., Mackenzie I.R., Cairns N.J., Swanson E., Boyer P.J., Drachman D.A., Jhaveri B.S., Karlawish J.H., Pestronk A., Smith T.W., et al. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol 65 (2006) 571-581. This study is the first comprehensive description of the neuropathology of 'Inclusion body myopathy with Paget's disease of bone and frontotemporal dementia' (IBMPFD) caused by mutations in VCP. The CNS pathology in IBMPFD is characterized by a novel pattern of ubiquitin pathology distinct from sporadic and familial FTLD-U, that is, type 4 (Figure 1).
9. •]).
10. •].
11. •].
12. Momeni P., Schymick J., Jain S., Cookson M.R., Cairns N.J., Greggio E., Greenway M.J., Berger S., Pickering-Brown S., Chio A., et al. Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol 6 (2006) 44
13. Pasinelli P., and Brown R.H. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7 (2006) 710-723. This is an outstanding review on recent advances in our understanding of the molecular genetics of amyotrophic lateral sclerosis.
14. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314 (2006) 130-133. In this study, the authors generated novel monoclonal antibodies to the ubiquitin pathology of FTLD-U leading to the identification of TDP-43 as the major disease protein. Antibodies to TDP-43 did not detect the pathology in a variety of other neurodegenerative characterized by inclusion pathology. However, TDP-43 was also detected in the UBI of ALS, providing the first molecular link between these two neurodegenerative disorders. Pathological TDP-43 was abnormally phosphorylated, ubiquitinated, and cleaved to generate C-terminal fragments from affected CNS regions.
15. Murphy J., Henry R., and Lomen-Hoerth C. Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol 64 (2007) 330-334
16. McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., and Trojanowski J.Q. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 58 (2001) 1803-1809
17. Mackenzie I.R., and Feldman H. Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. J Neuropathol Exp Neurol 64 (2005) 730-739
18. Talbot K., and Ansorge O. Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. Hum Mol Genet 15 Spec No 2 (2006) R182-R187
19. •]). In this study, the histological type correlated strongly with clinical phenotype.
20. ••].
21. Ou S.H., Wu F., Harrich D., Garcia-Martinez L.F., and Gaynor R.B. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 69 (1995) 3584-3596
22. Buratti E., and Baralle F.E. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 276 (2001) 36337-36343
23. Ayala Y.M., Pantano S., D'Ambrogio A., Buratti E., Brindisi A., Marchetti C., Romano M., and Baralle F.E. Human, Drosophila, and C. elegans TDP43: nucleic acid binding properties and splicing regulatory function. J Mol Biol 348 (2005) 575-588. To investigate the function of TDP-43, this study describes the cloning and characterization of TDP-43 homologs from Drosophila melanogaster and Caenorhabditis elegans. The proteins from human, fly, and worm showed striking similarities in their nucleic acid-binding specificity. However, differences in the structure of the glycine-rich C-terminal domain between human, fly, and worm implicated this domain in the splicing regulatory function of the protein.
24. Buratti E., Dork T., Zuccato E., Pagani F., Romano M., and Baralle F.E. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 20 (2001) 1774-1784
25. Mercado P.A., Ayala Y.M., Romano M., Buratti E., and Baralle F.E. Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene. Nucleic Acids Res 33 (2005) 6000-6010
26. Wang H.Y., Wang I.F., Bose J., and Shen C.K. Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics 83 (2004) 130-139
27. Buratti E., Brindisi A., Giombi M., Tisminetzky S., Ayala Y.M., and Baralle F.E. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem 280 (2005) 37572-37584. This study demonstrated that the C-terminal domain of TDP-43 is capable of binding directly to several proteins of the hnRNP family with well-defined splicing inhibitory activity including hnRNP A2/B1 and hnRNP A1. TDP-43 protein lacking the C-terminal region did not inhibit splicing because hnRNP-rich complexes were not formed at the earliest stages of spliceosomal assembly.
28. Acharya K.K., Govind C.K., Shore A.N., Stoler M.H., and Reddi P.P. cis-Requirement for the maintenance of round spermatid-specific transcription. Dev Biol 295 (2006) 781-790
29. Wang I.F., Reddy N.M., and Shen C.K. Higher order arrangement of the eukaryotic nuclear bodies. Proc Natl Acad Sci U S A 99 (2002) 13583-13588
30. Cairns N.J., Neumann M., Bigio E.H., Holm I.E., Troost D., Hatanpaa K.J., Foong C., White III C.L., Schneider J.A., Kretzschmar H.A., et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171 (2007) 227-240. This is a large survey study on 193 cases of familial and sporadic FTLD. The study confirmed the specificity of TDP-43 for the ubiquitin pathology in FTLD-U but not in other pathologies associated with FTLD including Pick's disease, corticobasal degeneration, progressive supranuclear palsy, and FTDP-17 because of MAPT gene mutations. The study also validated the classification scheme of FTLD-U and correlated the pathological subtypes with specific genetic abnormalities.
31. •].
32. •].
33. Seelaar H., Schelhaas H.J., Azmani A., Kusters B., Rosso S., Majoor-Krakauer D., de Rijik M.C., Rizzu P., ten B.M., van Doorn P.A., et al. TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. Brain 130 (2007) 1375-1385
34. Higashi S., Iseki E., Yamamoto R., Minegishi M., Hino H., Fujisawa K., Togo T., Katsuse O., Uchikado H., Furukawa Y., et al. Appearance pattern of TDP-43 in Japanese frontotemporal lobar degeneration with ubiquitin-positive inclusions. Neurosci Lett 419 (2007) 213-218
35. Tan C.F., Eguchi H., Tagawa A., Onodera O., Iwasaki T., Tsujino A., Nishizawa M., Kakita A., and Takahashi H. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol 113 (2007) 535-542. In this study, the brains and spinal cords from four cases of fALS because of SOD1 gene mutations was examined by TDP-43 immunohistochemistry and compared with sporadic ALS and fALS without SOD1 mutations. The UBI in both sporadic ALS and non-SOD1 fALS were TDP-43-immunoreactive. In contrast, the ubiquitin pathology in fALS with SOD1 gene mutations was not detected with antibodies to TDP-43. These data support the hypothesis that ALS because of SOD1 mutations reflects a disease pathway distinct from the sporadic disease counterpart.
36. Mackenzie I.R., Bigio E.H., Ince P.G., Geser F., Neumann M., Cairns N.J., Kwong L.K., Forman M.S., Ravits J., Stewart H., et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61 (2007) 427-434. This is a survey study investigating TDP-43 using both biochemistry and immunohistochemistry in a large series of ALS cases (n = 111) including fALS with and without SOD1 gene mutations. The UBI of all cases of sporadic ALS, ALS with dementia, and SOD1-negative fALS were immunoreactive with antibodies to TDP-43 including the detection of oligodendroglial inclusions that were not appreciated with immunostaining for ubiquitin. By contrast, the UBI of fALS with SOD1 gene mutations were not detected with TDP-43 immunohistochemistry. These findings implicate TDP-43 in the pathogenesis of ALS and support the hypothesis that fALS caused by SOD1 gene mutations may result from a different disease pathway that also affects motor neurons.
37. Neumann M., Kwong L.K., Truax A.C., Vanmassenhove B., Kretzschmar H.A., Van D.V., Clark C.M., Grossman M., Miller B.L., Trojanowski J.Q., et al. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol 66 (2007) 177-183. This study demonstrates abundant TDP-43-immunoreactive white matter pathology as a characteristic disease feature in 38 FTLD-U cases including 3 with PGRN mutations. The white matter inclusions are most probably oligodendrocytes based on morphology and double-labeling studies. These findings expanded the spectrum of TDP-43 pathology in FTLD-U and implicated white matter disease in the neurodegenerative process.
38. Neumann M., Mackenzie I.R., Cairns N.J., Boyer P.J., Markesbery W.R., Smith C.D., Taylor J.P., Kretzschmar H.A., Kimonis V.E., and Forman M.S. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol 66 (2007) 152-157. This study analyzed the ubiquitin pathology in IBMPFD associated with VCP gene mutations. The NII and DN were labeled with antibodies to TDP-43 leading to the hypothesis that VCP mutations lead to a dominant-negative loss or alteration of VCP function culminating in impaired degradation of TDP-43. This study supports the central role of TDP-43 as a common pathological substrate linking a variety of distinct patterns of FTLD-U pathology caused by different genetic alterations.
39. Robertson J., Sanelli T., Xiao S., Yang W., Horne P., Hammond R., Pioro E.P., and Strong M.J. Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. Neurosci Lett 420 (2007) 128-132
40. Geser F., Winton M.J., Kwong L.K., Xu Y., Xie S.X., Igaz L.M., Garruto R.M., Perl D.P., Galasko D., Lee V.M.Y., et al. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 115 (2008) 133-145
41. Hasegawa M., Arai T., Akiyama H., Nonaka T., Mori H., Hashimoto T., Yamazaki M., and Oyanagi K. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 130 (2007) 1386-1394
42. Rothstein J.D. TDP-43 in amyotrophic lateral sclerosis: pathophysiology or patho-babel?. Ann Neurol 61 (2007) 382-384. This very interesting commentary questions whether the TDP-43 inclusions in ALS represent a pathological curiosity or have 'real pathophysiological relevance'. Time will tell.
43. Leverenz J.B., Yu C.E., Montine T.J., Steinbart E., Bekris L.M., Zabetian C., Kwong L.K., Lee V.M.Y., Schellenberg G.D., and Bird T.D. A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. Brain 130 (2007) 1360-1374
44. Nakashima-Yasuda H., Uryu K., Robinson J., Xie S.X., Hurtig H., Duda J.E., Arnold S.E., Siderowf A., Grossman M., Leverenz J.B., et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114 (2007) 221-229
45. •].
46. Rollinson S., Snowden J.S., Neary D., Morrison K.E., Mann D.M., and Pickering-Brown S.M. TDP-43 gene analysis in frontotemporal lobar degeneration. Neurosci Lett 419 (2007) 1-4
47. Strong M.J., Volkening K., Hammond R., Yang W., Strong W., Leystra-Lantz C., and Shoesmith C. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci 35 (2007) 320-327. This study demonstrated that TDP-43 stabilizes low molecular weight neurofilament mRNA through a direct interaction with the 3′UTR. Thus, the sequestration of TDP-43 in cytosolic inclusions could contribute to the formation of neurofilament aggregates by destabilizing low molecular weight neurofilament message thereby altering the stoichiometry of neurofilament subunits in neurons.
48. Neumann M., Igaz L.M., Kwong L.K., Nakashima-Yasuda H., Kolb S.J., Dreyfuss G., Kretzschmar H.A., Trojanowski J.Q., and Lee V.M.Y. Absence of heterogeneous nuclear ribonucleoproteins and survival motor neuron protein in TDP-43 positive inclusions in frontotemporal lobar degeneration. Acta Neuropathol (Berl) 113 (2007) 543-548
49. Ahmed Z., Mackenzie I.R., Hutton M.L., and Dickson D.W. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 4 (2007) 7